117 related articles for article (PubMed ID: 16364249)
1. TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer.
Santos AM; Sousa H; Portela C; Pereira D; Pinto D; Catarino R; Rodrigues C; Araújo AP; Lopes C; Medeiros R
Biochem Biophys Res Commun; 2006 Feb; 340(1):256-62. PubMed ID: 16364249
[TBL] [Abstract][Full Text] [Related]
2. Linking TP53 codon 72 and P21 nt590 genotypes to the development of cervical and ovarian cancer.
Santos AM; Sousa H; Pinto D; Portela C; Pereira D; Catarino R; Duarte I; Lopes C; Medeiros R
Eur J Cancer; 2006 May; 42(7):958-63. PubMed ID: 16542834
[TBL] [Abstract][Full Text] [Related]
3. The influence of HER2 genotypes as molecular markers in ovarian cancer outcome.
Pinto D; Pereira D; Portela C; da Silva JL; Lopes C; Medeiros R
Biochem Biophys Res Commun; 2005 Oct; 335(4):1173-8. PubMed ID: 16112085
[TBL] [Abstract][Full Text] [Related]
4. TP53 codon 72 polymorphism associated with prognosis in patients with advanced gastric cancer treated with paclitaxel and cisplatin.
Kim JG; Sohn SK; Chae YS; Song HS; Kwon KY; Do YR; Kim MK; Lee KH; Hyun MS; Lee WS; Sohn CH; Jung JS; Kim GC; Chung HY; Yu W
Cancer Chemother Pharmacol; 2009 Jul; 64(2):355-60. PubMed ID: 19052714
[TBL] [Abstract][Full Text] [Related]
5. Association between TP53 and p21 genetic polymorphisms and acute side effects of radiotherapy in breast cancer patients.
Tan XL; Popanda O; Ambrosone CB; Kropp S; Helmbold I; von Fournier D; Haase W; Sautter-Bihl ML; Wenz F; Schmezer P; Chang-Claude J
Breast Cancer Res Treat; 2006 Jun; 97(3):255-62. PubMed ID: 16331344
[TBL] [Abstract][Full Text] [Related]
6. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.
Marsh S; Paul J; King CR; Gifford G; McLeod HL; Brown R
J Clin Oncol; 2007 Oct; 25(29):4528-35. PubMed ID: 17925548
[TBL] [Abstract][Full Text] [Related]
7. Elevated risk of squamous-cell carcinoma of the lung in heavy smokers carrying the variant alleles of the TP53 Arg72Pro and p21 Ser31Arg polymorphisms.
Popanda O; Edler L; Waas P; Schattenberg T; Butkiewicz D; Muley T; Dienemann H; Risch A; Bartsch H; Schmezer P
Lung Cancer; 2007 Jan; 55(1):25-34. PubMed ID: 17059853
[TBL] [Abstract][Full Text] [Related]
8. Platinum/paclitaxel-based chemotherapy in advanced ovarian carcinoma: glutathione S-transferase genetic polymorphisms as predictive biomarkers of disease outcome.
Medeiros R; Pereira D; Afonso N; Palmeira C; Faleiro C; Afonso-Lopes C; Freitas-Silva M; Vasconcelos A; Costa S; Osório T; Lopes C
Int J Clin Oncol; 2003 Jun; 8(3):156-61. PubMed ID: 12851839
[TBL] [Abstract][Full Text] [Related]
9. P53 gene status in patients with advanced serous epithelial ovarian cancer in relation to response to paclitaxel- plus platinum-based chemotherapy and long-term clinical outcome.
Gadducci A; Di Cristofano C; Zavaglia M; Giusti L; Menicagli M; Cosio S; Naccarato AG; Genazzani AR; Bevilacqua G; Cavazzana AO
Anticancer Res; 2006; 26(1B):687-93. PubMed ID: 16739339
[TBL] [Abstract][Full Text] [Related]
10. Prediction of TP53 status for primary cisplatin, fluorouracil, and leucovorin chemotherapy in ethmoid sinus intestinal-type adenocarcinoma.
Licitra L; Suardi S; Bossi P; Locati LD; Mariani L; Quattrone P; Lo Vullo S; Oggionni M; Olmi P; Cantù G; Pierotti MA; Pilotti S
J Clin Oncol; 2004 Dec; 22(24):4901-6. PubMed ID: 15611505
[TBL] [Abstract][Full Text] [Related]
11. ERCC1 genotype and phenotype in epithelial ovarian cancer identify patients likely to benefit from paclitaxel treatment in addition to platinum-based therapy.
Smith S; Su D; Rigault de la Longrais IA; Schwartz P; Puopolo M; Rutherford TJ; Mor G; Yu H; Katsaros D
J Clin Oncol; 2007 Nov; 25(33):5172-9. PubMed ID: 18024864
[TBL] [Abstract][Full Text] [Related]
12. Stathmin and tubulin expression and survival of ovarian cancer patients receiving platinum treatment with and without paclitaxel.
Su D; Smith SM; Preti M; Schwartz P; Rutherford TJ; Menato G; Danese S; Ma S; Yu H; Katsaros D
Cancer; 2009 Jun; 115(11):2453-63. PubMed ID: 19322891
[TBL] [Abstract][Full Text] [Related]
13. mdr-1 single nucleotide polymorphisms in ovarian cancer tissue: G2677T/A correlates with response to paclitaxel chemotherapy.
Gréen H; Söderkvist P; Rosenberg P; Horvath G; Peterson C
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):854-9. PubMed ID: 16467099
[TBL] [Abstract][Full Text] [Related]
14. Association of p53 and p21(CDKN1A/WAF1/CIP1) polymorphisms with oral cancer in Taiwan patients.
Bau DT; Tsai MH; Lo YL; Hsu CM; Tsai Y; Lee CC; Tsai FJ
Anticancer Res; 2007; 27(3B):1559-64. PubMed ID: 17595776
[TBL] [Abstract][Full Text] [Related]
15. ERCC1 codon 118 polymorphism is a useful prognostic marker in patients with pancreatic cancer treated with platinum-based chemotherapy.
Kamikozuru H; Kuramochi H; Hayashi K; Nakajima G; Yamamoto M
Int J Oncol; 2008 May; 32(5):1091-6. PubMed ID: 18425336
[TBL] [Abstract][Full Text] [Related]
16. G-308A TNF-alpha polymorphism is associated with an increased risk of invasive cervical cancer.
Duarte I; Santos A; Sousa H; Catarino R; Pinto D; Matos A; Pereira D; Moutinho J; Canedo P; Machado JC; Medeiros R
Biochem Biophys Res Commun; 2005 Aug; 334(2):588-92. PubMed ID: 16009345
[TBL] [Abstract][Full Text] [Related]
17. Genetic polymorphisms in TP53, nonsteroidal anti-inflammatory drugs and the risk of colorectal cancer: evidence for gene-environment interaction?
Tan XL; Nieters A; Hoffmeister M; Beckmann L; Brenner H; Chang-Claude J
Pharmacogenet Genomics; 2007 Aug; 17(8):639-45. PubMed ID: 17622940
[TBL] [Abstract][Full Text] [Related]
18. OGG1 Cys326 variant, allelic imbalance of chromosome band 3p25.3 and TP53 mutations in ovarian cancer.
Arcand SL; Provencher D; Mes-Masson AM; Tonin PN
Int J Oncol; 2005 Nov; 27(5):1315-20. PubMed ID: 16211227
[TBL] [Abstract][Full Text] [Related]
19. Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen.
Bertheau P; Turpin E; Rickman DS; Espié M; de Reyniès A; Feugeas JP; Plassa LF; Soliman H; Varna M; de Roquancourt A; Lehmann-Che J; Beuzard Y; Marty M; Misset JL; Janin A; de Thé H
PLoS Med; 2007 Mar; 4(3):e90. PubMed ID: 17388661
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of p21 protein expression in patients with pulmonary squamous cell carcinoma following induction chemotherapy.
Tamura M; Sawabata N; Kobayashi S; Umezu H; Seki N; Yoshii N; Karube Y; Araki O; Ishihama H; Nagai S; Miyoshi S
Ann Thorac Cardiovasc Surg; 2007 Feb; 13(1):9-14. PubMed ID: 17392664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
